TargetMol myh9 inhibition assay

Identification of <t>Myh9</t> as a direct binding target of Sa and evaluation of complex stability. A: Schematic representation of the chemoproteomic workflow using a biotin-labeled Sa probe in NIH3T3 cells. B: Coomassie blue-stained SDS-PAGE gel showing differential protein bands between treatment groups. The band marked by a dashed box was excised for LC-MS/MS analysis. C: Molecular docking model displaying the binding conformation of Sa with Myh9 and key interacting residues. D: Two-dimensional interaction diagram illustrating hydrogen bonds and hydrophobic interactions between Sa and Myh9. E–G: Molecular dynamics simulation of the Sa–Myh9 complex: (E) RMSD, (F) RMSF of chain D, and (G) Rg plots, reflecting structural stability, residue flexibility, and compactness over 100 ns. H–K: CETSA evaluating Myh9 thermal stability in A253 (H and J) and NIH3T3 (I and K) cells treated with Sa (10 μg/ml). Melting curves derived from CETSA illustrate increased thermal stability of Myh9. Data are presented as mean ± SD. P < 0.05, P < 0.01 versus control group. CETSA, cellular thermal shift assay; RMSD, root mean square deviation; RMSF, root mean square fluctuation; Rg, radius of gyration.

Myh9 Inhibition Assay, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/myh9 inhibition assay/product/TargetMol
Average 94 stars, based on 1 article reviews

myh9 inhibition assay - by Bioz Stars, 2026-05

94/100 stars

Buy from Supplier

myh9 1676 1791 (Beyotime)

Beyotime myh9 1676 1791

Primers used to construct different species PRA and truncated domains of PRA.

Myh9 1676 1791, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/myh9 1676 1791/product/Beyotime
Average 99 stars, based on 1 article reviews

myh9 1676 1791 - by Bioz Stars, 2026-05

99/100 stars

Buy from Supplier

Image Search Results

Identification of Myh9 as a direct binding target of Sa and evaluation of complex stability. A: Schematic representation of the chemoproteomic workflow using a biotin-labeled Sa probe in NIH3T3 cells. B: Coomassie blue-stained SDS-PAGE gel showing differential protein bands between treatment groups. The band marked by a dashed box was excised for LC-MS/MS analysis. C: Molecular docking model displaying the binding conformation of Sa with Myh9 and key interacting residues. D: Two-dimensional interaction diagram illustrating hydrogen bonds and hydrophobic interactions between Sa and Myh9. E–G: Molecular dynamics simulation of the Sa–Myh9 complex: (E) RMSD, (F) RMSF of chain D, and (G) Rg plots, reflecting structural stability, residue flexibility, and compactness over 100 ns. H–K: CETSA evaluating Myh9 thermal stability in A253 (H and J) and NIH3T3 (I and K) cells treated with Sa (10 μg/ml). Melting curves derived from CETSA illustrate increased thermal stability of Myh9. Data are presented as mean ± SD. P < 0.05, P < 0.01 versus control group. CETSA, cellular thermal shift assay; RMSD, root mean square deviation; RMSF, root mean square fluctuation; Rg, radius of gyration.

Journal: Journal of Lipid Research

Article Title: Sphinganine as a potentially relevant metabolite in pulmonary involvement of primary Sjögren’s syndrome

doi: 10.1016/j.jlr.2025.100961

Figure Lengend Snippet: Identification of Myh9 as a direct binding target of Sa and evaluation of complex stability. A: Schematic representation of the chemoproteomic workflow using a biotin-labeled Sa probe in NIH3T3 cells. B: Coomassie blue-stained SDS-PAGE gel showing differential protein bands between treatment groups. The band marked by a dashed box was excised for LC-MS/MS analysis. C: Molecular docking model displaying the binding conformation of Sa with Myh9 and key interacting residues. D: Two-dimensional interaction diagram illustrating hydrogen bonds and hydrophobic interactions between Sa and Myh9. E–G: Molecular dynamics simulation of the Sa–Myh9 complex: (E) RMSD, (F) RMSF of chain D, and (G) Rg plots, reflecting structural stability, residue flexibility, and compactness over 100 ns. H–K: CETSA evaluating Myh9 thermal stability in A253 (H and J) and NIH3T3 (I and K) cells treated with Sa (10 μg/ml). Melting curves derived from CETSA illustrate increased thermal stability of Myh9. Data are presented as mean ± SD. P < 0.05, P < 0.01 versus control group. CETSA, cellular thermal shift assay; RMSD, root mean square deviation; RMSF, root mean square fluctuation; Rg, radius of gyration.

Article Snippet: For the Myh9 inhibition assay, cells were pretreated with 2 μM Blebbistatin (TargetMol, Shanghai, China) for 4 h in serum-free medium.

Techniques: Binding Assay, Labeling, Staining, SDS Page, Liquid Chromatography with Mass Spectroscopy, Residue, Derivative Assay, Control, Thermal Shift Assay

Functional role of Myh9 in Sa-induced epithelial injury and fibroblast activation. A: Relative mRNA expression of Myh9 in submandibular gland tissues as measured by qRT-PCR. B: Immunohistochemical staining analysis and (C) quantitative analysis of the expression of Myh9 in lung tissues. D and E: Western blot analysis (D) and corresponding quantification (E) of Myh9 protein expression in A253 cells treated with increasing concentrations of Sa. F and G: Western blot (F) and densitometric analysis (G) of Myh9 expression in NIH3T3 cells treated with Sa or TGF-β1 (positive control). H and I: Western blot (H) and quantification (I) of AQP5 expression in A253 cells treated with Sa, with or without the Myh9 inhibitor blebbistatin. J and K: Western blot (J) and quantification (K) of fibronectin and α-SMA protein levels in NIH3T3 cells treated with Sa, with or without blebbistatin. Data are presented as mean ± SD. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001; ns, not significant. # P < 0.05, ## P < 0.01 Sa group with 4-PBA treatment. α-SMA, alpha-smooth muscle actin; 4-PBA, 4-phenylbutyric acid; AQP5, aquaporin-5

Journal: Journal of Lipid Research

Article Title: Sphinganine as a potentially relevant metabolite in pulmonary involvement of primary Sjögren’s syndrome

doi: 10.1016/j.jlr.2025.100961

Figure Lengend Snippet: Functional role of Myh9 in Sa-induced epithelial injury and fibroblast activation. A: Relative mRNA expression of Myh9 in submandibular gland tissues as measured by qRT-PCR. B: Immunohistochemical staining analysis and (C) quantitative analysis of the expression of Myh9 in lung tissues. D and E: Western blot analysis (D) and corresponding quantification (E) of Myh9 protein expression in A253 cells treated with increasing concentrations of Sa. F and G: Western blot (F) and densitometric analysis (G) of Myh9 expression in NIH3T3 cells treated with Sa or TGF-β1 (positive control). H and I: Western blot (H) and quantification (I) of AQP5 expression in A253 cells treated with Sa, with or without the Myh9 inhibitor blebbistatin. J and K: Western blot (J) and quantification (K) of fibronectin and α-SMA protein levels in NIH3T3 cells treated with Sa, with or without blebbistatin. Data are presented as mean ± SD. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001; ns, not significant. # P < 0.05, ## P < 0.01 Sa group with 4-PBA treatment. α-SMA, alpha-smooth muscle actin; 4-PBA, 4-phenylbutyric acid; AQP5, aquaporin-5

Article Snippet: For the Myh9 inhibition assay, cells were pretreated with 2 μM Blebbistatin (TargetMol, Shanghai, China) for 4 h in serum-free medium.

Techniques: Functional Assay, Activation Assay, Expressing, Quantitative RT-PCR, Immunohistochemical staining, Staining, Western Blot, Positive Control

Molecular mechanism of Sa induces salivary hyposecretion and pulmonary fibrosis in pSS through the ATF6–Myh9 signaling pathway. Sa, sphinganine; pSS, primary Sjögren’s syndrome.

Journal: Journal of Lipid Research

Article Title: Sphinganine as a potentially relevant metabolite in pulmonary involvement of primary Sjögren’s syndrome

doi: 10.1016/j.jlr.2025.100961

Figure Lengend Snippet: Molecular mechanism of Sa induces salivary hyposecretion and pulmonary fibrosis in pSS through the ATF6–Myh9 signaling pathway. Sa, sphinganine; pSS, primary Sjögren’s syndrome.

Article Snippet: For the Myh9 inhibition assay, cells were pretreated with 2 μM Blebbistatin (TargetMol, Shanghai, China) for 4 h in serum-free medium.

Techniques:

Journal: Frontiers in Microbiology

Article Title: Identification of MYH9 Key Domain Involved in the Entry of PRRSV Into Permissive Cells

doi: 10.3389/fmicb.2022.865343

Figure Lengend Snippet: Primers used to construct different species PRA and truncated domains of PRA.

Article Snippet: The cytotoxic effects of blebbistatin, mouse-PRA, human-PRA, monkey-PRA, and MYH9 1676−1791 were evaluated using the Cell Counting Kit-8 (CCK-8) assay (Beyotime, Nanjing, China).

Techniques: Construct

Knockdown of MYH9 of PK-15 CD163 , BHK-21 CD163 , and HEK-293T CD163 cell lines reduce PRRSV replication. PK-15 CD163 (A) , BHK-21 CD163 (B) , and HEK-293T CD163 (C) cells were transfected with MYH9 siRNA or NC siRNA, respectively, for 12 h, and then infected with PRRSV strain SD16 (1 MOI) for 48 h. PRRSV replication was measured by mRNA and protein levels using qRT-PCR and Western blot analysis. The data shown are representatives from three independent experiments and subjected to Student's t -test. *** P < 0.001 vs. cells treated without siRNA; ## P < 0.01 vs. cells treated without siRNA; ### P < 0.001 vs. cells treated without siRNA.

Journal: Frontiers in Microbiology

Article Title: Identification of MYH9 Key Domain Involved in the Entry of PRRSV Into Permissive Cells

doi: 10.3389/fmicb.2022.865343

Figure Lengend Snippet: Knockdown of MYH9 of PK-15 CD163 , BHK-21 CD163 , and HEK-293T CD163 cell lines reduce PRRSV replication. PK-15 CD163 (A) , BHK-21 CD163 (B) , and HEK-293T CD163 (C) cells were transfected with MYH9 siRNA or NC siRNA, respectively, for 12 h, and then infected with PRRSV strain SD16 (1 MOI) for 48 h. PRRSV replication was measured by mRNA and protein levels using qRT-PCR and Western blot analysis. The data shown are representatives from three independent experiments and subjected to Student's t -test. *** P < 0.001 vs. cells treated without siRNA; ## P < 0.01 vs. cells treated without siRNA; ### P < 0.001 vs. cells treated without siRNA.

Techniques: Knockdown, Transfection, Infection, Quantitative RT-PCR, Western Blot

The key domain of MYH9 for PRRSV inhibition in MARC-145 cells. (A) Schematic diagram of truncation fragments located in the C-terminal of MYH9. MARC-145 cells were inoculated with the mixture of PRRSV 0.1 MOI and truncated protein of PRA (2.5 μM), and the key domain of MYH9 for anti-PRRSV was determined using qPCR (B) and Western blot (C–F) . The data shown are representatives from three independent experiments and subjected to one-way ANOVA. *** P < 0.001 vs. PCV2-Cap protein treated cells.

Journal: Frontiers in Microbiology

Article Title: Identification of MYH9 Key Domain Involved in the Entry of PRRSV Into Permissive Cells

doi: 10.3389/fmicb.2022.865343

Figure Lengend Snippet: The key domain of MYH9 for PRRSV inhibition in MARC-145 cells. (A) Schematic diagram of truncation fragments located in the C-terminal of MYH9. MARC-145 cells were inoculated with the mixture of PRRSV 0.1 MOI and truncated protein of PRA (2.5 μM), and the key domain of MYH9 for anti-PRRSV was determined using qPCR (B) and Western blot (C–F) . The data shown are representatives from three independent experiments and subjected to one-way ANOVA. *** P < 0.001 vs. PCV2-Cap protein treated cells.

Techniques: Inhibition, Western Blot

The blocking effect of MYH9 1676−1791 against PRRSV SD16 infection in PAMs. PAMs were infected with PRRSV SD16 at 0.1 MOI pre-incubated with MYH9 1676−1791 (2.5, 5, and 10 μM), respectively, and the mRNA (A) and protein levels (B) of PRRSV N gene were measured by qPCR and Western blot. The data shown are representatives from three independent experiments and subjected to one-way ANOVA. ** P < 0.01 vs. 0 μM MYH9 1676−1791 treated cells; *** P < 0.001 vs. 0 μM MYH9 1676−1791 treated cells.

Journal: Frontiers in Microbiology

Article Title: Identification of MYH9 Key Domain Involved in the Entry of PRRSV Into Permissive Cells

doi: 10.3389/fmicb.2022.865343

Figure Lengend Snippet: The blocking effect of MYH9 1676−1791 against PRRSV SD16 infection in PAMs. PAMs were infected with PRRSV SD16 at 0.1 MOI pre-incubated with MYH9 1676−1791 (2.5, 5, and 10 μM), respectively, and the mRNA (A) and protein levels (B) of PRRSV N gene were measured by qPCR and Western blot. The data shown are representatives from three independent experiments and subjected to one-way ANOVA. ** P < 0.01 vs. 0 μM MYH9 1676−1791 treated cells; *** P < 0.001 vs. 0 μM MYH9 1676−1791 treated cells.

Techniques: Blocking Assay, Infection, Incubation, Western Blot

The soluble MYH9 1676−1791 against PRRSV-2 isolates in MARC-145 and PAM cells. MARC-145 cells (A) or PAMs (B) were infected with PRRSV-2 isolates (JXA1, GD-HD, CH-1a, and VR-2332) at 0.1 MOI pre-mixed with MYH9 1676−1791 (5 μM), and the mRNA and protein levels of N gene were measured by qPCR and Western blot. The data shown are representatives from three independent experiments and subjected to Student's t -test. ** P < 0.01 vs. the cells infected with the same virus and treated with PBS; *** P < 0.001 vs. the cells infected with the same virus and treated with PBS.

Journal: Frontiers in Microbiology

Article Title: Identification of MYH9 Key Domain Involved in the Entry of PRRSV Into Permissive Cells

doi: 10.3389/fmicb.2022.865343

Figure Lengend Snippet: The soluble MYH9 1676−1791 against PRRSV-2 isolates in MARC-145 and PAM cells. MARC-145 cells (A) or PAMs (B) were infected with PRRSV-2 isolates (JXA1, GD-HD, CH-1a, and VR-2332) at 0.1 MOI pre-mixed with MYH9 1676−1791 (5 μM), and the mRNA and protein levels of N gene were measured by qPCR and Western blot. The data shown are representatives from three independent experiments and subjected to Student's t -test. ** P < 0.01 vs. the cells infected with the same virus and treated with PBS; *** P < 0.001 vs. the cells infected with the same virus and treated with PBS.

Techniques: Infection, Western Blot, Virus

The soluble MYH9 1676−1791 against PRRSV-1 isolates in PAM cells. MYH9 1676−1791 (5 μM) was pre-mixed with indicated PRRSV-1 strains (MOI = 0.1) at 37°C for 1 h before infecting PAM cells. Relative PRRSV GZ11-G1 (A) and PRRSV P073-3 (B) N gene mRNA levels were monitored via qPCR at 24 hpi. The data shown are representatives from three independent experiments and subjected to Student's t -test. *** P < 0.001 vs. 0 μM MYH9 1676−1791 treated cells. Gene copy numbers of PRRSV GZ11-G1 (C) and PRRSV P073-3 (D) N in cell culture supernatant at indicated MYH9 1676−1791 concentrations of treatment were determined. The data shown are representatives from three independent experiments and subjected to Student's t -test. $$$ P < 0.001, in comparison to 0 μM MYH9 1676−1791 treated cells.

Journal: Frontiers in Microbiology

Article Title: Identification of MYH9 Key Domain Involved in the Entry of PRRSV Into Permissive Cells

doi: 10.3389/fmicb.2022.865343

Figure Lengend Snippet: The soluble MYH9 1676−1791 against PRRSV-1 isolates in PAM cells. MYH9 1676−1791 (5 μM) was pre-mixed with indicated PRRSV-1 strains (MOI = 0.1) at 37°C for 1 h before infecting PAM cells. Relative PRRSV GZ11-G1 (A) and PRRSV P073-3 (B) N gene mRNA levels were monitored via qPCR at 24 hpi. The data shown are representatives from three independent experiments and subjected to Student's t -test. *** P < 0.001 vs. 0 μM MYH9 1676−1791 treated cells. Gene copy numbers of PRRSV GZ11-G1 (C) and PRRSV P073-3 (D) N in cell culture supernatant at indicated MYH9 1676−1791 concentrations of treatment were determined. The data shown are representatives from three independent experiments and subjected to Student's t -test. $$$ P < 0.001, in comparison to 0 μM MYH9 1676−1791 treated cells.

Techniques: Cell Culture, Comparison

The polyclonal anti-MYH9 1676−1791 serum reduces PRRSV infection in MARC-145 and PAM cells. MARC-145 (A) or PAM (B) cells were infected with PRRSV SD16 at an MOI of 0.1 in the presence of various concentrations of mouse anti-MYH9 1676−1791 polyclonal serum or mouse negative serum, and relative changes in the mRNA level of PRRSV N gene were determined by qPCR at 24 hpi. The data shown are representatives from three independent experiments and subjected to one-way ANONA. * P < 0.05 vs. cells treated with mouse negative serum, *** P < 0.001 vs. cells treated with mouse negative serum. (C) IFA assay results confirmed the PRRSV inhibition in MARC-145 and PAM cells with anti-MYH9 1676−1791 polyclonal serum (1:20) treated at 24 hpi (left). Scale bar, 100 μm. Histograms represent the percentage of PRRSV-positive cells, performed using ImageJ software (right). The data shown are representatives from three independent experiments and subjected to Student's t -test. && P < 0.01, & && P < 0.001.

Journal: Frontiers in Microbiology

Article Title: Identification of MYH9 Key Domain Involved in the Entry of PRRSV Into Permissive Cells

doi: 10.3389/fmicb.2022.865343

Figure Lengend Snippet: The polyclonal anti-MYH9 1676−1791 serum reduces PRRSV infection in MARC-145 and PAM cells. MARC-145 (A) or PAM (B) cells were infected with PRRSV SD16 at an MOI of 0.1 in the presence of various concentrations of mouse anti-MYH9 1676−1791 polyclonal serum or mouse negative serum, and relative changes in the mRNA level of PRRSV N gene were determined by qPCR at 24 hpi. The data shown are representatives from three independent experiments and subjected to one-way ANONA. * P < 0.05 vs. cells treated with mouse negative serum, *** P < 0.001 vs. cells treated with mouse negative serum. (C) IFA assay results confirmed the PRRSV inhibition in MARC-145 and PAM cells with anti-MYH9 1676−1791 polyclonal serum (1:20) treated at 24 hpi (left). Scale bar, 100 μm. Histograms represent the percentage of PRRSV-positive cells, performed using ImageJ software (right). The data shown are representatives from three independent experiments and subjected to Student's t -test. && P < 0.01, & && P < 0.001.

Techniques: Infection, Inhibition, Software

myh9 inhibition assay Search Results

Image Search Results